1-3 of 3
Zheng Yuan
Close
Sort by
Journal Articles

Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL)

Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Zonder A Jeffrey, MD, Vishal Kukreti, MD FRCPC, Stefan O Schoenland, MD, Arnaud Jaccard, MD, Angela Dispenzieri, MD, Adam D. Cohen, MD, Deborah Berg, RN, MSN, Zheng Yuan, PhD, Ai-Min Hui, MD PhD, Palladini Giovanni, MD PhD, Raymond L. Comenzo, MD
Journal: Blood
Blood (2014) 124 (21): 3450.
https://doi.org/10.1182/blood.V124.21.3450.3450
Published: 2014
Journal Articles

Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study.

Irene M Ghobrial, Jean-Luc Harousseau, Steven P Treon, Brianna Harris, Courtney E Lin, Zheng Yuan, Karim Benhadji, James E Wooldridge, Veronique Leblond
Journal: Blood
Blood (2009) 114 (22): 3867.
https://doi.org/10.1182/blood.V114.22.3867.3867
Published: 2009
Journal Articles

A Phase I Safety Study of Enzastaurin Plus Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.

Irene M Ghobrial, Nikhil C Munshi, Brianna N Harris, Zheng Yuan, Nichole M Porter, Robert L Schlossman, Jacob P Laubach, Kenneth C. Anderson, Courtney E Lin, James E Wooldridge, Paul G Richardson, Rafat Abonour
Journal: Blood
Blood (2009) 114 (22): 1870.
https://doi.org/10.1182/blood.V114.22.1870.1870
Published: 2009